SERA Stock Overview
A women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sera Prognostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.22 |
| 52 Week High | US$9.91 |
| 52 Week Low | US$2.10 |
| Beta | 1.0 |
| 1 Month Change | -31.69% |
| 3 Month Change | -50.11% |
| 1 Year Change | -76.03% |
| 3 Year Change | 30.59% |
| 5 Year Change | n/a |
| Change since IPO | -81.34% |
Recent News & Updates
Recent updates
Sera Prognostics: Initiating With Hold, Potential Of PreTRM Test, But Uncertain Commercial Timeline
Apr 15Sera Prognostics (NASDAQ:SERA) Is In A Strong Position To Grow Its Business
Jan 11
We're Not Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn
Jul 19Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Mar 24Sera Prognostics: The Pregnancy Company On A Hot Streak
Jan 10Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?
Oct 03We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth
Jun 15We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate
Feb 16We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Nov 03A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening
Aug 10We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Jul 21Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation
Apr 06We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely
Dec 15Shareholder Returns
| SERA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.7% | -9.0% | -0.3% |
| 1Y | -76.0% | -15.0% | 8.1% |
Return vs Industry: SERA underperformed the US Biotechs industry which returned -15% over the past year.
Return vs Market: SERA underperformed the US Market which returned 8.1% over the past year.
Price Volatility
| SERA volatility | |
|---|---|
| SERA Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: SERA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SERA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 64 | Zhenya Lindgardt | www.sera.com |
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction.
Sera Prognostics, Inc. Fundamentals Summary
| SERA fundamental statistics | |
|---|---|
| Market cap | US$83.63m |
| Earnings (TTM) | -US$32.99m |
| Revenue (TTM) | US$115.00k |
727.2x
P/S Ratio-2.5x
P/E RatioIs SERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SERA income statement (TTM) | |
|---|---|
| Revenue | US$115.00k |
| Cost of Revenue | US$105.00k |
| Gross Profit | US$10.00k |
| Other Expenses | US$33.00m |
| Earnings | -US$32.99m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 8.70% |
| Net Profit Margin | -28,685.22% |
| Debt/Equity Ratio | 0% |
How did SERA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 22:19 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sera Prognostics, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Patrick Donnelly | Citigroup Inc |
| François Brisebois | Oppenheimer & Co. Inc. |